Celldex Therapeutics, Inc. (NASDAQ:CLDX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday, November 7th.
Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated a “buy” rating and issued a $9.00 price target on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Zacks Investment Research upgraded Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price objective on the stock in a report on Tuesday, July 11th. ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, BidaskClub cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $6.31.
Shares of Celldex Therapeutics (NASDAQ CLDX) opened at $2.91 on Tuesday. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $4.91.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.07. The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $1.30 million. Celldex Therapeutics had a negative return on equity of 46.94% and a negative net margin of 1,088.58%. The business’s revenue was up 77.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) earnings per share. sell-side analysts forecast that Celldex Therapeutics will post -0.93 EPS for the current fiscal year.
WARNING: “Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives “Buy” Rating from HC Wainwright” was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/11/19/celldex-therapeutics-cldx-buy-rating-reiterated-at-hc-wainwright.html.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC acquired a new position in Celldex Therapeutics during the third quarter worth $101,000. OxFORD Asset Management LLP acquired a new position in Celldex Therapeutics during the third quarter worth $122,000. Dimensional Fund Advisors LP lifted its stake in Celldex Therapeutics by 3.6% during the third quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock worth $2,465,000 after purchasing an additional 29,604 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Celldex Therapeutics during the third quarter worth $242,000. Finally, Ameriprise Financial Inc. lifted its stake in Celldex Therapeutics by 15.6% during the third quarter. Ameriprise Financial Inc. now owns 441,411 shares of the biopharmaceutical company’s stock worth $1,263,000 after purchasing an additional 59,629 shares in the last quarter. Hedge funds and other institutional investors own 53.06% of the company’s stock.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.